Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106334 · ClinicalTrials.gov registry record · Phase 1
Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants
A Phase 1 study of Obesity and Healthy Volunteers, sponsored by Shionogi.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06106334 is a Phase 1 study of Obesity and Healthy Volunteers that has completed, run by Shionogi. The registered enrollment target is 14 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06106334, a Phase 1 study of Obesity and Healthy Volunteers, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and co-administration with itraconazole
Conditions Studied
Interventions
- DRUG Itraconazole
- DRUG S309309
Study Locations (1)
Texas
- Fortrea Clinical Research Unit Inc. - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2024-02-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106334
The ClinicalTrials.gov registry entry for NCT06106334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Itraconazole is the first listed.
NCT06106334 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06106334 about?
NCT06106334 is a clinical study titled "Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants". The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and co-administration with itraconazole
What is the current status of trial NCT06106334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-11-15. Estimated completion is 2024-02-14.
What conditions does trial NCT06106334 study?
This clinical trial studies the following conditions: Obesity, Healthy Volunteers.
What interventions are being tested in trial NCT06106334?
The interventions under investigation include: Itraconazole (DRUG), S309309 (DRUG).
Who is sponsoring clinical trial NCT06106334?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106334 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.